Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 15, 2014 | IPO | — | — | — | — | Detail |
Apr 16, 2014 | Series B | $36M | 8 | Livzon Mabpharm | — | Detail |
Jul 1, 2012 | Series Unknown | $5M | 2 | — | — | Detail |
Apr 1, 2012 | Series Unknown | $8.08M | 2 | — | — | Detail |
Jan 1, 2011 | Series A | $34M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Livzon Mabpharm | Yes | Series B |
5AM Ventures | — | Series B |
Adage Capital Management | — | Series B |
Gibralt Capital Corporation | — | Series B |
Greenwoods Investment | — | Series B |
Montreux Equity Partners | — | Series B |
Mousse Partners | — | Series B |
TPG Biotech | — | Series B |
Epirus Biopharmaceuticals has acquired 2 organizations. Their most recent acquisition was Zalicus on Jul 15, 2014. They acquired Zalicus for 0.